Can Disease Management Target Patients Most Likely to Generate High Costs? The Impact of Comorbidity by Charlson, Mary et al.
Can Disease Management Target Patients Most Likely to Generate
High Costs? The Impact of Comorbidity
Mary Charlson, MD
1, Robert E. Charlson, MD
2, William Briggs, PhD
1, and James Hollenberg, MD
1
1DivisionofGeneralInternalMedicine,ExecutiveDirector,CenterforComplementaryandIntegrativeMedicine,Weill Medical College of Cornell
University, 525 East 68th Street, Box 46, New York, NY 10021, USA;
2Yale New Haven Hospital, New Haven, CT, USA.
CONTEXT: Disease management programs are increas-
ingly used to manage costs of patients with chronic
disease.
OBJECTIVE: We sought to examine the clinical char-
acteristics and measure the health care expenditures of
patients most likely to be targeted by disease manage-
ment programs.
DESIGN: Retrospective analysis of prospectively
obtained data.
SETTING: A general medicine practice with both faculty
and residents at an urban academic medical center.
PARTICIPANTS: Five thousand eight hundred sixty-one
patients enrolled in the practice for at least 1 year.
MAIN OUTCOMES: Annual cost of diseases targeted by
disease management.
MEASUREMENTS: Patients’ clinical and demographic
information were collected from a computer system
used to manage patients. Data included diagnostic
information, medications, and resource usage over
1 year. We looked at 10 common diseases targeted by
disease management programs.
RESULTS: Unadjusted annual median costs for chron-
ic diseases ranged between $1,100 and $1,500. Con-
gestive heart failure ($1,500), stroke ($1,500), diabetes
($1,500), and cancer ($1,400) were the most expensive.
As comorbidity increased, annual adjusted costs in-
creased exponentially. Those with comorbidity scores of
2 or more accounted for 26% of the population but 50%
of the overall costs.
CONCLUSIONS: Costs for individual chronic conditions
vary within a relatively narrow range. However, the
costs for patients with multiple coexisting medical
conditions increase rapidly. Reducing health care costs
will require focusing on patients with multiple comorbid
diseases, not just single diseases. The overwhelming
impact of comorbidity on costs raises significant con-
cerns about the potential ability of disease management
programs to limit the costs of care.
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INTRODUCTION
In recent years, cost of caring for individuals with chronic
disease has increasingly come to dominate health care expen-
ditures in this country, with an estimated 78% of total health
care resources soon to be devoted to individuals with chronic
disease.
1 Among approaches to curtail rising health care costs,
disease management programs have shown promise in im-
proving outcomes and the quality of care for chronic illness.
Disease management is a systematic, population-based ap-
proach to patient care that aims to curb utilization by
optimizing the process of care, increasing efficiency and
managing the “total” disease.
2–6 In practice, most disease
management programs involve a combination of patient
education and compliance programs, treatment guidelines,
and other interventions to design a comprehensive approach to
managing a patient’s disease. These programs are frequently
either outsourced to pharmaceutical benefits managers or
other for profit organizations, or developed in-house as part
of HMOs or other insurers. In recent years, these programs
have grown rapidly, with revenues rising from $85M in 1997 to
more than $600M in 2002,
7 while targeting specific chronic
illnesses as congestive heart failure, diabetes, depression, and
asthma, among others.
The goal of this paper is to use prospectively acquired data
to determine characteristics of patients at risk for the highest
utilization, focusing on chronic diseases commonly addressed
by disease management programs. By determining the actual
cost of such conditions, in both unadjusted and adjusted
terms, such data will demonstrate whether targeting patients
with single chronic conditions is an efficient strategy for
reaching high cost patients or whether targeting of patients
with multiple chronic illnesses is required.
METHODS
Overview
We conducted a cohort study of 5,861 patients cared for at an
academic medical practice at New York-Presbyterian Hospital
over a 1-year period. To be included in the study, these
patients had to have been followed for 1-year or more by
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464physicians in the practice. The study involved the collection of
demographic, clinical, and cost data from the hospital data
systems. Though study patients could have any diagnosis, our
analysis focused on 10 common diseases targeted by disease
management programs: congestive heart failure, dementia,
ischemic heart disease, stroke, diabetes, cancer, asthma,
COPD, depression and hypertension. The study was approved
by the hospital’s institutional review board (IRB).
Collection of Data
Patients were identified and cost data was compiled through
CLIMACS
©, a practice management system developed by 1 of
the authors (JPH), for a 1-year period beginning December 1,
1993. Among 15,186 patients who had at least 1 physician
visit during that 1-year period, 7,041 were excluded because
they were new to the practice. Another 2,284 patients were
excluded because they had received care for less than a year
prior to the beginning of the study. To be included, patients
had to be established patients of the practice, receiving care for
at least 1 year before December 1, 1993. This ensured the
longitudinal capture of clinical information. This data provided
the basis for previous papers about resident versus attending
and about depression in primary care practices.
8,9
In total, 5,861 patients met these criteria, and the data on
diagnoses and comorbidity was accumulated from all of the
patient’s visits to the practice over at least a 1-year period.
Patients who did not meet criteria tended to be younger and
were more often male. Data on the 0.4% of patients who died
during the year were included. The clinical data collected
includes appointments, laboratory tests, radiology tests, con-
sultations, procedures, prescriptions, outpatient diagnoses,
and patient billing. ICD-9 codes were assigned in this system
by physicians at the conclusion of each visit for billing
purposes. Diagnoses were cumulative, unlimited in number
and new diagnoses were added as they occurred. Therefore,
CLIMACS
© provides a prospectively collected database of
demographics, appointments, ICD-9 diagnoses, medications,
and resource utilization.
Clinical and Demographic Characteristics
Patients’ clinical and demographic characteristics were collect-
ed from the above data system. Patient age was based on the
age on the date of study data collection, defined as December1,
1993. The Charlson comorbidity index was used to measure
the burden of comorbid illness.
10 This comorbidity index
assigns a weight of 1 to myocardial infarction, congestive heart
failure, peripheral vascular disease, cerebrovascular disease,
dementia, chronic pulmonary disease, ulcer disease, mild liver
disease, and diabetes (whether type I or type II). However,
diabetes (type I or II) with end organ damage (neuropathy,
nephropathy, or retinopathy), any tumor, leukemia, and
lymphoma all have a weight of 2, while moderate or severe
liver disease has a weight of 3. Metastatic solid tumor and
AIDS have a weight of 6. The score is calculated by adding
weights for each patient disease, with possible scores ranging
from 0 to 32; higher scores are associated with poorer
prognosis. The Deyo adaptation for ICD-9 data was used to
identify the presence of specific comorbid diseases.
11 Comor-
bidity was assessed from ambulatory records; hence, the
discharge-related group coding did not affect the comorbidity.
We previously reported that comparing the CLIMACS data to
patient records regarding diabetes mellitus, asthma, and
chronic obstructive pulmonary disease showed an undercoding
rate of 0.8% for diabetes, and 7.7% for asthma and COPD.
8
Resource Utilization
Cost data was collected for inpatient and outpatient events.
The total cost includes the cost of ambulatory visits, laboratory
tests, radiographic tests, consultations, and hospital charges.
The New York Hospital cost accounting system (Transition
Systems Inc, Boston Mass) tracked inpatient costs, and
converted charges to costs by using specific cost-to-charge
ratios. Each department had a specific cost-to-charge ratio,
i.e., radiology and microbiology. Cost-to-charge ratios did not
vary by payer or plan. CLIMACS data allowed for the assess-
ment of the number of ambulatory visits, laboratory and
radiology tests, specialty consultations, and other miscella-
neous services such as vaccinations or procedures. Data on
ambulatory resource utilization was converted from charges to
cost using the specific ratio of cost-to-charges for each
category of service. Services such as skilled nursing, home
health, outpatient pharmaceutical, were not offered by the
hospital or included in the charges.
Not all costs of care were able to be captured; external
providers, including visits to physicians outside the practice
and tests ordered and performed in outside laboratories, were
not part of this analysis. Similarly, hospital costs include only
those costs at New York-Presbyterian Hospital; if patients were
hospitalized elsewhere, the costs were not captured. To assess
the rate of undercoding, a 1% random sample of patients was
contacted, and rate of hospitalization at other facilities was
6.3% among the 158 patients interviewed by telephone.
Statistical Analysis
We calculated the unadjusted annual costs associated with 10
chronic diseases often targeted by disease management pro-
grams. These included congestive heart failure, dementia,
ischemic heart disease, stroke, diabetes, cancer, asthma,
COPD, depression, and hypertension. These costs were com-
pared to the unadjusted annual costs of the remainder of the
study population without that specific disease. The percentage
of total costs represented by those patients with each individ-
ual comorbidity score was then calculated, and compared to
the percentage of the total population represented by each
comorbidity score. We then calculated adjusted annual costs
for each specific disease, using the statistical software R
12 to
perform regression modeling. The multivariate model deter-
mining adjusted costs considered age, sex, specific chronic
diseases, and the Charlson comorbidity index. The adjusted
annual costs for each illness were then calculated for each
comorbidity index score.
Adjusted Costs of Chronic Diseases
A regression model was built to predict the log of total cost
adjusting for age, sex, individual diseases, and Charlson
comorbidity index. The log of total cost was necessary to bring
this response in line with typical regression assumptions.
Because the relation between age and cost was not linear and
the nonlinearity had a significant impact on cost, a restricted
cubic spline (with 4 knots chosen dynamically) was used to
465 Charlson et al.: Can Disease Management Target High-Cost Patients JGIMallow nonlinear effects for age. This, again, is fairly standard
practice for data of this type. Also, we primarily sought to
control for age and were not, per se, interested in estimating a
simplified functional dependence on age.
Nonlinearities were unneeded for the comorbidity index.
Interactions of sex and age, sex and comorbidity, and (linear)
age and comorbidity were included in each model. Interactions
of age and comorbidity were found unnecessary.
RESULTS
Total Unadjusted Costs
The average age was 56. Typical of many primary care
practices, significantly more patients were women.
13,14 As
shown in Table 1, 32% had Medicare; 30%, Medicaid; 12%,
managed care (mainly PPO plans); and 8%, employee plans.
Unadjusted median costs and their interquartile range for
various chronic diseases commonly addressed by disease
management programs are listed in Table 2. The percent of
patients with each condition is also shown. The most expensive
diseases were congestive heart failure ($1,500; in annual
unadjusted costs), stroke ($1,500), diabetes ($1,500), and
cancer ($1,400). Dementia ($1,100), COPD ($1,200), and
hypertension ($1,200) were least expensive. The overall median
annual cost for a random patient in this study was $810. Mean
charges, often reported, are much higher reflecting the skewed
nature of cost data. There were no gender differences in cost or
comorbidity. The cost outcomes were not significantly related to
plan type, after adjusting for age, sex, and comorbidity.
Higher comorbid burden of illness was associated with a
larger percentage of overall costs (Table 2). The proportion of
overall costs attributed to increasing comorbidity is detailed in
Table 3. Though accounting for more than 43% of the study
population, individuals with a comorbidity score of 0 accounted
for just 23% of the cost. Likewise, patients with a comorbidity
score of 1 accounted for 30% of the population and 27% of the
cost. However, those individuals with comorbidity scores of 2 or
more accounted for just 26% of the population, but slightly
more than 50% of the overall cost of care. In unadjusted terms,
costs for individuals with higher comorbidity increased steeply,
ranging from $1,300 for a score of 2 to $1,600 for a score of 3 to
$3,000 with scores of 6.
Figure 1 shows the modeled mean annual costs of various
chronic diseases calculated for a female of median age (57) with
the stated disease (the effect of sex was small; the modeled
average was exponentiated to produce numbers in real dollars.
Thus, the adjusted cost—for each disease—was calculated by
inputing the values of adjusted comorbidity and the median sex
(f) and age, and computing the result). The horizontal axis is the
adjusted comorbidity index, which is found by subtracting the
weighting of each stated disease from the patient’s comorbidity
score for just those patients with the stated disease. Thus,
adjusted comorbidity scores of 0 are for patients who had the
stated disease but no other (except possibly for those diseases
that do not contribute weights to the comorbidity index).
Calculating the adjusted comorbidity allows us to remove the
effect of each disease while still showing that costs increase by
adding to a patient’s comorbid burden.
As (adjusted) comorbidity rises, regardless of the disease,
total yearly adjusted mean cost increases rapidly, as the shape
of the curve reveals. Yearly costs were especially high among
those patients with comorbidity scores of 2 or more. Disease
was still important to predict costs, however. For example,
patients with cancer and an adjusted comorbidity score of 6
had very high costs, while patients with hypertension had
lowest costs of all patients with an adjusted comorbidity score
of 6. Although hypertension is lowest and cancer is highest,
the mean costs are remarkably similar at lower levels of
Table 1. Demographics of the Population
Parameters Percentage
<20 0.3 (0.9)
20–29 7.6 (14.8)
30–39 13.5 (20.2)
40–49 15.3 (17.3)
50–59 17.2 (16.2)
60–69 18.6 (14.3)
70–79 16.9 (10.7)
80–89 8.9 (4.9)
>90 1.7 (0.8)
Female 72
Medicare 32
Medicaid 29.5
Self-pay 16.5
Employee 8.4
Managed 11.9
Table 2. The Yearly Unadjusted Median Costs of Patients with and
without Specific Chronic Diseases
Chronic
diseases
Percentage
of population
with disease
Median
unadjusted
annual cost
with specific
disease (inner-
quartile range)
Median
unadjusted
annual cost
without specific
disease (inner-
quartile range)
Congestive
Heart Failure
8 $1,500 ($3,500) $770 ($1,100)
Dementia 2 $1,100 ($2,500) $800 ($1,200)
Ischemic
heart disease
4 $1,300 ($2,100) $790 ($1,200)
Stroke 3 $1,500 ($1,900) $800 ($1,200)
Diabetes 18 $1,500 ($1,900) $700 ($1,000)
Cancer 8 $1,400 ($1,800) $760 ($1,200)
Asthma 15 $1,300 ($1,600) $760 ($1,100)
COPD 10 $1,200 ($1,300) $770 ($1,200)
Depression 10 $1,300 ($1,600) $770 ($1,200)
Hypertension 45 $1,200 ($1,400) $550 ($900)
AIDS 1 $1,800 ($4,300) $800 ($1,200)
Note that the patients in the second column did not have the specified
disease but may have had other diseases; these numbers are averages
across all other diseases patients may have had, so not too much should
be read in the differences between these numbers.
Table 3. Distribution of Costs and Patients According to Total
Comorbidity
Charlson
comorbidity scale
Percentage
of total cost
Percentage
of patients
Median
cost ($)
0 21 43 $500
1 25 30 $870
2 23 14 $1,300
3 15 7 $1,600
4 7 3 $1,600
5 3.4 1.4 $2,200
6 2.5 0.85 $3,000
≥7 1.4 0.25 $2,400
(N=5,861)
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scores (2 to 4) had similar adjusted costs, regardless of
disease. Overall cost escalation follows a remarkably similar
pattern with increasing comorbidity.
Figure 2 shows the distribution of patients’ adjusted comor-
bidity scores conditioned on each disease. For the 478 patients
with congestive heart failure, 129 (27%) had an adjusted
comorbidity score of 0 (as follows from the definition of this
score); 92 patients (19%) had an adjusted comorbidity score of
1, which means that each patient had some other disease with a
weight of 1. The same trend occurred in patients with diabetes.
Of a total population of 1,030 patients with diabetes, 355 (34%)
had an adjusted comorbidity score of 0, while 189 (18%) had an
adjusted comorbidity score of 1. Though significantly less in
number, patients with higher levels of comorbidity accounted
for a notable fraction of the overall costs of care, as noted above.
The interesting thing to note is that the distribution of
comorbidity scores remains essentially the same regardless of
the base disease (see Fig. 2). In effect, the data suggests that
higher costs are driven by the aggregate comorbidity burden,
regardless of the specific diseases.
DISCUSSION
The goal of this study has been to examine the annual costs of
chronic diseases often targeted by disease management pro-
grams. In this study, we found that unadjusted costs varied
within a relatively narrow range ($1,100 to $1,600). There were
only small differences between patients who had only 1 of the
following conditions: congestive heart failure, dementia, ische-
mic heart disease, stroke, COPD, depression, and hyperten-
sion. The costs increased rapidly when patients had 2, 3, or 4
different comorbid conditions. The cost of care increased
rapidly with increasing comorbidity, with a small percentage
of patients (26%) with comorbidity ≥ 2 accounting for half
(50%) the total costs.
Several other recent studies of the cost of various chronic
diseases have shown some divergence in the actual cost
figures.
15–17 Many reasons for such discrepancies exist includ-
ing differences in the populations, and differences in cost-to-
charge ratios. The cost of care at an academic institution such
as ours may be different from other centers,
18,19 and medical
services and their costs have been shown to exhibit geographic
variation.
20,21 Because we did not use claims data, our study
undoubtedly missed costs incurred outside New York Hospital,
and our data also did not include expenditures related to
prescription drugs or emergency room visits more easily
captured in a claims-based system.
In our study, a small percentage of the patients accounted
for a large percentage of the costs, a result that agrees with
other studies on the costs of chronic illness. In some studies,
perhaps as little as 10–20% of patients have accounted for
more than 70–80% of the resources,
4,22 a result has been
repeated in other studies that assess the costs of chronic
illness.
16 Though not often specified, our results suggest that
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Figure 1. The adjusted cost of each chronic condition according the adjusted level of comorbidity (for a female of median age).
467 Charlson et al.: Can Disease Management Target High-Cost Patients JGIMpatients with multiple coexisting conditions may represent
that group of patients responsible for the lion’s share of the
overall costs of care.
The importance of measuring the cost of chronic disease in
different settings bears directly on the future of disease
management. Though evolving, disease management pro-
grams continue to be driven by the fundamental principle of
providing quality health care at a reduced cost.
2,5,6 There is
more evidence about improving outcomes than reducing
costs.
23–27 Disease management has not shown consistent
cost savings in randomized trials.
28,29 In fact, surprisingly few
studies have actually evaluated the effect of disease manage-
ment programs on health care utilization, and those that did,
often reported modest or inconsistent findings.
30,31 Further
complicating the picture of disease management, encouraging
findings are often short term (within a 1-year window), and
usually do not include the administrative costs of the disease
management programs themselves.
It has been suggested that explanation for such contradic-
tory results, at least in part, lies in the different populations
enrolled in disease management programs mean to target.
2,3,32
To reduce costs, programs must target high-risk patient
populations, where interventions targeted at reducing hospi-
talizations, emergency room visits, and the like, can theoret-
ically lead to reduced resource utilization over a defined
window. Enrollment of low risk patients in such programs is
unlikely to show benefits. This emphasis on profitable subsets
of the larger insured population has led several authors to
raise questions concerning disease management’s ability to
focus on general disease prevention in relatively well patients,
instead of short-term cost savings involving relatively sick
ones.
2
Our study, however, questions the ultimate ability of disease
management programs to target patients most likely to drive
overall resource utilization. Patients with multiple coexisting
conditions present a major challenge to disease management,
as they are not immediately suited to having a single protocol
manage their care. Yet these same patients are the ones that,
in our study, accounted for the majority of overall costs. As
comorbidity score increased, cost of care increased exponen-
tially; put intuitively, the more complex a patient, the more
expensive the cost of care. Though some authors have
suggested that disease management programs expand “hori-
zontally”, providing services for comorbid conditions in addi-
tion to primary disease,
6 there is currently no simple way to
stack disease management programs for such complex
patients. Recently, limitations and potential risks of applying
clinical practice guidelines to patients with multiple comorbid
diseases has been highlighted.
33 However, there is evidence
that chronic disease self-management programs, developed by
Lorig and colleagues and designed to enhance self-efficacy,
may reduce utilization.
34–37
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Figure 2. The distribution of patients’ adjusted comorbidity scores for each disease. An adjusted comorbidity score of 0 always means the
percent of patients with the stated disease only. Adjusted comorbidity scores greater than 0 indicate the percent of patients with a disease or
diseases in additional to the stated disease.
468 Charlson et al.: Can Disease Management Target High-Cost Patients JGIMOur study was limited by several factors. First, for each
patient in the practice, not all costs were captured. Patients
could have seen providers and undergone hospitalization
outside of our practice and New York-Presbyterian Hospital.
Second, certain disease groups, notably cancer, have cost data
that is probably underrepresented. Specifically, the cost of
cancer chemotherapy was not tracked by our cost accounting
system, accounting for the relatively low cost of cancer patients
in our study.
Ultimately, disease management programs have much to
offer patients regarding empowering patients through educa-
tion, improving medication management, and encouraging
them to become active members in management of their
disease. Indeed, the literature continues to show quality
improvements with many disease-specific management pro-
grams. However, whether they offer significant promise to a
changing health care payment system remains to be seen. To
make a significant impact on health care costs, programs need
to focus on the highest cost drivers in the system: patients with
multiple coexisting conditions. Efforts to reduce cost must
focus on patients with the highest aggregate comorbidity
burden; our data suggests that specific combination for
diseases matters less.
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